Diabetic nephropathy-What are the unmet needs?

Diabetes Research and Clinical Practice

Volumn 82, Issue SUPPL. 1, 2008, Pages

  Luk, Andrea ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; End stage renal disease; Obesity

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST;

ALBUMINURIA; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; HUMAN; KIDNEY FAILURE; OBESITY; OXIDATIVE STRESS; RISK FACTOR;

ANEMIA; ASIA; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; OBESITY; RISK FACTORS;

EID: 55249083701     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.033     Document Type: Article

References (68)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. York D.A., Rössner S., Caterson J., Chen C.M., James W.P., Kumanyika S., et al. Prevention conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group 1: worldwide demographics of obesity. Circulation 110 (2004) e463-e470
3. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes. Diabetes Care 27 (2004) 1047-1053
4. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet (2005) 1415-1428
5. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1998) 1595-1607
6. Lakka H.M., Laaksonen D.E., and Lakka T.A. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 288 (2002) 2709-2716
7. Ninomiya J.K., L'Italien G., Crigui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third National Health and Nutrition Examination Survey. Circulation 209 (2004) 42-46
8. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143 (2005) 722-728
9. Svatikova A., Wolk R., Gami A.S., Pohanka M., and Somers V.K. Interactions between obstructive sleep apnoea and the metabolic syndrome. Curr. Diab. Rep. 5 (2005) 53-58
10. Ehrmann D.A., Liljenquist D.R., Kasza K., Azziz R., Legro R.S., and Ghazzi M.N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 91 (2006) 48-53
11. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., et al. The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. 140 (2004) 167-174
12. Roglic G., Unwin N., Bennett P.H., Matheres C., Tuomilehto J., Nag S., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28 (2005) 2130-2135
13. So W.Y., Yang X., Ma R.C., Kong A.P., Lam C.W., Ho C.C., et al. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes. Metab. Res. Rev. 24 (2008) 238-246
14. So W.Y., Kong A.P., Ma R.C., Ozaki R., Szeto C.C., Chan N.N., et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29 9 (2006) 2046-2052
15. Yang X., Ma R.C., So W.Y., Kong A.P., Ko G.T., Ho C.S., et al. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc. diabetol. 7 (2008) 9
16. Yang X., So W.Y., Kong A.P., Ma R.C., Ko G.T., Ho C.S., et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am. J. Cardiol. 101 (2008) 596-601
17. Yang X.L., So W.Y., Kong A.P., Ho C.S., Lam C.W., Ng M.H., et al. Modified end-stage renal disease risk score for Chinese type 2 diabetic patients-the Hong Kong Diabetes Registry. Diabetologia 50 (2007) 1348-1350
18. Yang X., So W.Y., Kong A.P., Ho C.S., Lam C.W., Stevens R.J., et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 30 (2007) 65-70
19. Yang X., So W.Y., Tong P.C., Ma R.C., Kong A.P., Lam C.W., et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch. Intern. Med. 168 (2008) 451-457
20. Yang X.L., So W.Y., Ma R.C.W., Ko T.C., Kong A.P.S., Wng Q., et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocrine-Related Cancer 15 2 (2008) 597-607
21. Pecoits-Filho R., Lindholm B., and Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol. Dial. Transplant. 17 Suppl. 11 (2002) 28-31
22. Ritz E., Rychlik I., Locatelli F., and Halimi S. End stage renal failure in type 2 diabetes: a medical catastrophy of worldwide dimensions. Am. J. Kidney Dis. 34 (1999) 795-808
23. Karter A., Ferrara A., Liu J., Moffet H., Ackerson L., and Selby J. Ethnic disparities in diabetic complications in an insured population. JAMA 287 (2002) 2519-2527
24. Parving H.H., Lewis J.B., Ravid M., Remuzzi G., and Hunsicker L.G. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 69 11 (2006) 2057-2063
25. Chan J.C.N., Wat N.M.S., So W.Y., Lam K.S.L., Chua C.T., Wong T.S., et al. On behalf of the Asian RENAAL Study Investigators: RAAS blockade and renal disease in type 2 diabetic patients: an Asian perspective from the RENAAL Study. Diabetes Care 27 (2004) 874-879
26. Wang Y., Ng M.C.Y., Lee S.C., So W.Y., Tong P.C., Cockram C.S., et al. Phenotypic heterogeneity and associations of tow aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003) 2410-2415
27. Wang Y., Ng M.C.Y., So W.Y., Tong P.C., Ma R.C., Chow C.C., et al. Prognostic effect of insertion/deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care 28 (2005) 348-354
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
29. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
30. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Prac. 28 (1995) 103-117
31. Bakris G.L., Williams M., Dworkin L., Wlliott W.K., Epstein M., Toto R., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 36 (2000) 646-661
32. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (2001) 851-860
33. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
34. Remuzzi G., Perico N., Macia M., and Ruggenenti P. The role of renin angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 68 Suppl. 99 (2005) S57-S65
35. Navarro J.E., Milena F.J., Mora C., Leon C., Claverie F., Flores C., et al. Tumour necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. 68 Suppl. 99 (2005) S98-S102
36. Stenvinkel P., Andersson A., Wang T., Lindholm B., Bergstrom J., Palmblad J., et al. Do ACE-inhibitors suppress tumour necrosis factor-α production in advanced chronic renal failure. J. Int. Med. 246 (1999) 503-507
37. Luk A., Ma R.C.W., So W.Y., Kong A.P.S., Ozaki R., Ng V., et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5874 patients with type 2 diabetes-a 5-year prospective analysis of the Hong Kong diabetes registry, Diabetes Care, (2008) 10.2337/dc08-0971.
38. Kambham N., Markowitz G.S., Valeri A.M., Lin J., and D'Agati V.D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59 (2001) 1498-1509
39. Iseki K., Ikemiya Y., Kinjo K., Inoue T., Iseki C., and Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 54 (2004) 1870-1876
40. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., and Go A.S. Body mass index and risk for end-stagge renal disease. Ann. Intern. Med. 144 (2006) 21-28
41. Bagby S.P. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease. J. Am. Soc. Nephrol. 15 (2004) 2775-2791
42. Kamijo A., Kimura K., Sugaya T., Mayamouchi M., Hase H., Kaneko T., et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 62 (2002) 1628-1637
43. Wisse B.E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15 (2004) 2792-2800
44. Adelman R.D. Obesity and renal disease. Curr. Opin. Nephrol. Hypertens. 11 (2002) 331-335
45. Tong P.C., Lee K.F., So W.Y., Ng M.H., Chan W.B., Lo M.K., et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 27 (2004) 216-222
46. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Inflammation and microalbuminuria in non-diabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. 58 (2000) 1703-1710
47. Wong C.K., Ho A.W., Tong P.C., Yeung C.Y., Kong A.P., Lun S.W., et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin. Exp. Immunol. 149 (2007) 123-131
48. Wong C.K., Ho A.W., Tong P.C., Yeung C.Y., Chan J.C., Kong A.P., et al. Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy. J. Clin. Immunol. 28 (2008) 36-43
49. Cheng A.Y., Kong A.P., Wong V.W., So W.Y., Chan H.L., Ho C.S., et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia 49 8 (2006) 1777-1784
50. Crook E., Penumalee S., Gavini B., and Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 28 (2005) 2187-2191
51. Thomas M.C., MacIsaac R.J., Tsalamandris C., Molyneaux L., Goubina I., Fulcher G., et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant. 19 (2004) 1792-1797
52. Thomas M.C., MacIsaac R.J., Tsalamandris C., Power D., and Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 26 (2003) 1164-1169
53. Thomas M.C., Cooper M.E., Tsalamandris C., MacIsaac R., and Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern. Med. 165 (2005) 466-469
54. Keane W.F., Brenner B.M., de Zeeuw D., Grunfeld J.-P., McGill J., Mitch W.E., et al. The risk of developing end stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kindey Int. 63 (2003) 1499-1507
55. Vlagopoulos P.T., Tighiouart H., Weiner D.E., Griffith J., Pettitt D., Salem D.N., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J. Am. Soc. Nephrol. 16 (2005) 3403-3410
56. Broom J. Anaemia in diabetic renal disease: an under-estimated risk factor. Acta Diabetol. 39 Suppl. 1 (2002) S2
57. Drueke T.B., Locatelli F., Clyne N., Eckardt K., MacDougall I.C., Tsakiris D., Burger H.U., and Scherhag A. Normalization of hemoglobin level in patients with chronic kidney diseases and anemia. N. Engl. J. Med. 355 (2006) 2071-2084
58. Singh A.K., Szczdch L., Tang K.L., Barnhart H., Sapp S., Wolfson M., and Reddan D. Correction of anemia with Epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355 (2006) 2085-2098
59. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 66 (2004) 753-760
60. Kuriyama S., Tomonari H., Yoshida H., Hashimoto T., Kawaguchi Y., and Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 (1997) 176-185
61. Dean B.B., Dylan M., Gano Jr. A., Knight K., Ofman J.J., and Levine B.S. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr. Med. Res. Opin. 21 (2005) 981-987
62. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358 (2008) 580-591
63. Kong A.P., Yang X., Ko G.T., So W.Y., Chan W.B., Ma R.C., et al. Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care 30 (2007) 953-959
64. Grant R.W., Buse J.B., and Meigs J.B. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 28 2 (2005) 337-442
65. Grant R.W., Devita N.G., Singer D.E., and Meigs J.B. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 26 5 (2003) 1408-1412
66. So W.Y., Tong P.C., Ko G.T., Leung W.Y., Chow C.C., Yeung V.T., et al. Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes. Am. J. Manage. Care 9 9 (2003) 606-615
67. Wu J.Y., Leung W.Y., Chang S., Lee B., Zee B., Tong P.C., et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 333 7567 (2006) 522
68. Leung W.Y.S., So W.Y., Tong P.C.Y., Chan N.N., and Chan J.C.N. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am. J. Med. 118 (2005) 1414.e1421-1414.e1427